Mindset Pharma Inc. (MSSTF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mindset Pharma Inc. (MSSTF) trades at $0.5381. Mindset Pharma Inc. is a Canadian biotechnology company focused on developing psychedelic medicines for neurological and psychiatric disorders. Their primary focus is the development of MSP-1014. Market cap: $54.5M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for MSSTF: MSSTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MSSTF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MSSTF: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Mindset Pharma Inc. (MSSTF) Healthcare & Pipeline Overview
Mindset Pharma Inc., a Canadian biotech firm, specializes in psychedelic drug development targeting neurological and psychiatric conditions. With a focus on its lead candidate, MSP-1014, the company operates in the emerging psychedelic medicine market, characterized by high risk and high potential reward.
What Is the Investment Thesis for MSSTF?
Mindset Pharma presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine market. The company's focus on developing novel compounds, particularly MSP-1014, could potentially address significant unmet needs in neurological and psychiatric disorders. However, the company's negative P/E ratio of -4.01 and a substantial negative profit margin of -425.2% highlight the inherent financial risks associated with early-stage biotechnology companies. Successful completion of clinical trials and regulatory approvals are critical catalysts for future growth. Investors should carefully consider the company's limited operating history, reliance on future funding, and the evolving regulatory landscape surrounding psychedelic medicines.
Based on FMP financials and quantitative analysis
MSSTF Key Highlights
Market capitalization of $54.5M, indicating a small-cap company with potential for growth but also higher volatility.
- Negative P/E ratio of -4.01, reflecting the company's current lack of profitability due to ongoing research and development expenses.
- Gross margin of 100.0%, suggesting strong potential profitability if the company can successfully commercialize its drug candidates.
- Beta of -0.10, indicating a low correlation with the overall market, which may offer some downside protection during market downturns.
- Focus on MSP-1014, a psychedelic drug candidate, representing a concentrated bet on the success of a single compound.
Who Are MSSTF's Competitors?
MSSTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BSTG Biostage, Inc. | $4.03 | +0.75% | $57.8M | 44 |
| HITC Healthcare Integrated Technologies, Inc. | $0.29 | +0.00% | $52.8M | 38 |
| HRPMF Herantis Pharma Oyj | $3.51 | +0.00% | $59.5M | 44 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| KDEVF Karolinska Development AB (publ) | $0.26 | +0.00% | $68.9M | 56 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MSSTF's Key Strengths?
Proprietary drug candidates in the emerging psychedelic medicine market.
- Experienced management team with expertise in drug development.
- Strong intellectual property portfolio.
- Potential to address unmet needs in neurological and psychiatric disorders.
What Are MSSTF's Weaknesses?
Limited operating history and revenue generation.
- Reliance on future funding to support research and development.
- High cash burn rate.
- Concentration of pipeline on a single drug candidate (MSP-1014).
What Could Drive MSSTF Stock Higher?
Publication of preclinical or clinical trial data for MSP-1014.
- Announcement of strategic partnerships or collaborations.
- Filing of Investigational New Drug (IND) application with regulatory agencies.
- Advancements in the regulatory landscape for psychedelic medicines.
- Increasing investor interest in the psychedelic medicine market.
What Are the Key Risks for MSSTF?
Financial-distress signal — its Altman Z-Score of -2.79 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for its drug candidates.
- Competition from other companies developing psychedelic medicines.
- Adverse side effects from psychedelic drugs.
- High cash burn rate and reliance on future funding.
- Negative public perception of psychedelic drugs.
What Are the Growth Opportunities for MSSTF?
- Advancement of MSP-1014 through clinical trials: The successful completion of Phase I, II, and III clinical trials for MSP-1014 would be a major catalyst for Mindset Pharma. Positive results could lead to increased investor confidence, partnerships with larger pharmaceutical companies, and ultimately, regulatory approval and commercialization. The timeline for this is dependent on trial progress, with potential for initial data readouts within the next 1-2 years.
- Expansion of drug pipeline: Developing additional psychedelic drug candidates beyond MSP-1014 would diversify Mindset Pharma's portfolio and reduce its reliance on a single compound. This could involve exploring different chemical structures, targeting new indications, or developing novel delivery methods. A broader pipeline would enhance the company's long-term growth prospects and attract further investment. This expansion could begin within the next 2-3 years.
- Strategic partnerships and collaborations: Partnering with larger pharmaceutical companies or research institutions could provide Mindset Pharma with access to additional funding, expertise, and resources. Collaborations could accelerate the development and commercialization of its drug candidates, as well as expand its market reach. Such partnerships could materialize within the next year, depending on the progress of clinical trials and business development efforts.
- Intellectual property protection: Securing patents and other forms of intellectual property protection for its drug candidates and technologies is crucial for Mindset Pharma's long-term success. Strong IP protection would create barriers to entry for competitors and enhance the company's competitive advantage. The company is actively pursuing patent applications and expects to strengthen its IP portfolio over the next several years.
- Regulatory approvals and commercialization: Obtaining regulatory approvals from health authorities in Canada, the United States, and other countries is essential for Mindset Pharma to commercialize its drug candidates. Successful commercialization would generate revenue and establish the company as a leader in the psychedelic medicine market. The timeline for regulatory approvals is uncertain but could potentially occur within the next 3-5 years, depending on clinical trial outcomes and regulatory processes.
What Opportunities Does MSSTF Have?
- Growing acceptance of psychedelic therapies.
- Increasing investment in psychedelic medicine research and development.
- Potential for strategic partnerships and collaborations.
- Expansion into new therapeutic areas and markets.
What Are MSSTF's Competitive Advantages?
- Proprietary psychedelic drug candidates.
- Intellectual property protection through patents.
- Expertise in psychedelic drug development.
- First-mover advantage in the emerging psychedelic medicine market.
What Does MSSTF Do?
Mindset Pharma Inc., based in Toronto, Canada, is a biotechnology company dedicated to the discovery, development, and commercialization of psychedelic medicines. The company's mission is to address unmet needs in neurological and psychiatric disorders through innovative drug candidates. Mindset Pharma is focused on creating next-generation psychedelic compounds designed to improve upon existing treatments. Their primary focus is on the development of MSP-1014, a novel psychedelic drug candidate. The company operates primarily in Canada, with potential for future expansion into other markets as its drug pipeline progresses. Mindset Pharma aims to establish itself as a leader in the psychedelic medicine space by developing proprietary compounds and securing intellectual property rights. The company's strategy involves preclinical and clinical trials to demonstrate the safety and efficacy of its drug candidates, with the ultimate goal of obtaining regulatory approvals and commercializing its products. Mindset Pharma is navigating the evolving regulatory landscape surrounding psychedelic medicines, working to advance its pipeline in a responsible and ethical manner.
What Products and Services Does MSSTF Offer?
- Develops psychedelic medicines for neurological and psychiatric disorders.
- Focuses on creating next-generation psychedelic compounds.
- Conducts preclinical and clinical trials to evaluate drug safety and efficacy.
- Seeks regulatory approvals for its drug candidates.
- Aims to commercialize its products in Canada and other markets.
- Develops MSP-1014, a psychedelic drug candidate.
How Does MSSTF Make Money?
- Develops and patents novel psychedelic compounds.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through drug sales after regulatory approval.
- Raises capital through equity financing to fund research and development.
What Industry Does MSSTF Operate In?
Mindset Pharma operates in the rapidly evolving psychedelic medicine industry, which is gaining increasing attention for its potential to treat various mental health disorders. The market is characterized by a growing acceptance of psychedelic therapies and increasing investment in research and development. Competitors include companies like BioStar Technology Group (BSTG), and others exploring psychedelic compounds for therapeutic applications. The industry faces regulatory hurdles and requires significant capital investment to conduct clinical trials and obtain regulatory approvals. Mindset Pharma's success depends on its ability to navigate these challenges and differentiate itself through innovative drug candidates.
Who Are MSSTF's Key Customers?
- Patients with neurological and psychiatric disorders.
- Healthcare providers who prescribe psychedelic medicines.
- Pharmaceutical companies that partner with Mindset Pharma.
- Research institutions that collaborate with Mindset Pharma.
Key Financial Metrics
Its free cash flow yield is 0.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.9%, the inverse of the P/E and a quick read on earnings relative to price.
Mindset Pharma Inc. (MSSTF) Valuation Context
Valued at $54.5M, MSSTF is classified as a micro-cap stock.
Company Profile
Mindset Pharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO James Andre-Charles Lanthier. MSSTF has traded publicly since 2021.
Financial Health
Mindset Pharma Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.79 places it in the distress zone, a signal of elevated financial risk.
MSSTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary drug candidates in the emerging psychedelic medicine market.
- Experienced management team with expertise in drug development.
- Strong intellectual property portfolio.
- Potential to address unmet needs in neurological and psychiatric disorders.
Bear Case
- Limited operating history and revenue generation.
- Reliance on future funding to support research and development.
- High cash burn rate.
- Concentration of pipeline on a single drug candidate (MSP-1014).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MSSTF Latest News
No recent news available for MSSTF.
MSSTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MSSTF.
Price Targets
Wall Street price target analysis for MSSTF.
MSSTF MoonshotScore
What does this score mean?
The MoonshotScore rates MSSTF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: James Andre-Charles Lanthier
CEO
James Andre-Charles Lanthier serves as the Chief Executive Officer of Mindset Pharma Inc. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy, business development, and capital markets. He has held leadership positions in various companies, contributing to their growth and development. Lanthier's expertise lies in identifying and executing strategic opportunities, building strong teams, and driving shareholder value. His education includes a strong foundation in business and finance, providing him with the skills necessary to lead Mindset Pharma in the competitive biotechnology landscape.
Track Record: Under James Andre-Charles Lanthier's leadership, Mindset Pharma has focused on advancing its pipeline of psychedelic drug candidates, particularly MSP-1014. He has overseen the company's efforts to secure intellectual property protection and establish strategic partnerships. Lanthier has also been instrumental in raising capital to fund the company's research and development activities. His strategic decisions have positioned Mindset Pharma as a player in the emerging psychedelic medicine market.
MSSTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Mindset Pharma may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Lower trading volumes and liquidity.
- Higher bid-ask spreads.
- Increased risk of delisting or going out of business.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's risk factors and potential liabilities.
- Check for any regulatory actions or legal disputes involving the company.
- Consult with a financial advisor before investing.
- Focus on developing psychedelic medicines for neurological and psychiatric disorders.
- Development of MSP-1014, a psychedelic drug candidate.
- Presence of a CEO (James Andre-Charles Lanthier).
- Company is based in Toronto, Canada.
- Gross Margin of 100.0%.
Mindset Pharma Inc. Healthcare Stock: Key Questions Answered
What does Mindset Pharma Inc. do?
Mindset Pharma Inc. is a Canadian biotechnology company focused on the development and commercialization of psychedelic medicines for the treatment of neurological and psychiatric disorders. The company's primary focus is on creating next-generation psychedelic compounds, with its lead drug candidate being MSP-1014.
What do analysts say about MSSTF stock?
As of March 17, 2026, there is no readily available analyst consensus on MSSTF stock due to its OTC listing and limited coverage. Key valuation metrics such as P/E ratio (-4.01) and profit margin (-425.2%) reflect the company's early stage and ongoing investments in research and development.
What are the main risks for MSSTF?
The main risks for Mindset Pharma Inc. include the inherent uncertainties associated with drug development, such as the potential for clinical trial failures, regulatory hurdles, and competition from other companies in the psychedelic medicine space. The company's high cash burn rate and reliance on future funding also pose financial risks.
What are the key factors to evaluate for MSSTF?
Evaluate MSSTF on fundamentals, analyst consensus, and risk factors. Mindset Pharma presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine market. Not financial advice.
How frequently does MSSTF data refresh on this page?
MSSTF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MSSTF's recent stock price performance?
Mindset Pharma Inc. (MSSTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidates in the emerging psychedelic medicine market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MSSTF overvalued or undervalued right now?
Mindset Pharma Inc. (MSSTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MSSTF before investing?
Before investing in Mindset Pharma Inc. (MSSTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.
- AI analysis pending for MSSTF.